Orthogonal platform enhances protein separation and characterisation
Enables labs around the world to generate more useful information from complex proteins, antibodies, polypeptides and polysaccharides.
Postnova Analytics reports on the extended data available through integrating its AF2000 MultiFlow Flow Field-Flow Fractionation (FFF) platform with its SC2000 modular multi-detector Size Exclusion chromatography (SEC) system.
Drawing on over three decades of cutting-edge separations leadership, Postnova has designed an advanced orthogonal system that allows both SEC and FFF separations to be carried out on the same sample within one instrument platform. The result is enabling labs around the world to generate more useful information from even complex proteins, antibodies, polypeptides and polysaccharides.
As both separation techniques in the Postnova 2000 Series FFF/SEC system can use the same optimised detector set - UV, RI and MALS (Multi Angle Light Scattering) realising the enhanced applications potential of the integrated system is achieved with minimal redundancy using an automatic switching value and software upgrade kit.
Offering orthogonally operating separation techniques in same platform, the Postnova 2000 Series FFF/SEC system delivers unmatched diagnostic flexibility across an increased application range. The system can be run with different eluents, pH and wide-ranging temperature conditions making it an ideal platform for the characterization of natural or synthetic macromolecules.
Postnova FFF technology employs a unique crossflow field in which samples are separated by their dynamic diffusion based on molar mass or particle size. Because of this design and the absence of any stationary phase, separations are performed without exerting shear forces and stress on the molecules.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance